When the Health Practitioners Disciplinary Tribunal found Dr Caroline Wheeler guilty of professional misconduct for prescribing ivermectin during COVID, it did more than discipline one GP.
It reignited a deeper question:
Who does medicine ultimately serve — the patient, or the protocol?
The Pandemic Power Shift
During COVID, emergency powers reshaped clinical decision-making worldwide.
Remdesivir — an antiviral developed by Gilead Sciences — received emergency authorization and later formal approval for certain hospitalized patients.
Financially, it became one of the fastest-scaling therapeutics in modern history:
• Gilead reported approximately $2.8 billion in remdesivir revenue in 2020
• Approximately $5.6 billion in 2021
• Total pandemic-era revenue exceeded $10 billion globally
Those figures are not opinion. They are publicly reported corporate earnings.
At the same time, emergency liability frameworks such as the U.S. PREP Act provided broad protections to manufacturers and administrators of COVID countermeasures.
The structure was clear:
Mass procurement.
Government contracts.
Liability shield.
Historic revenues.
The Ebola History
Before COVID, remdesivir was tested in the 2018–2019 Ebola PALM trial in the Democratic Republic of Congo.
The study compared four treatments. Two monoclonal antibody therapies (REGN-EB3 and mAb114) significantly outperformed both remdesivir and ZMapp.
The remdesivir arm was discontinued after rendering a mortality rate of approximately 53% in trials. Superior therapies were identified.
Still the 'professionals' setting the Covid treatment protocols say that does not prove remdesivir was “dangerous.”
But it does show it was not the most effective antiviral in that context.
By the time COVID emerged, remdesivir did not carry a record of dramatic clinical success.
COVID Outcomes: Modest Benefit
Major trials during COVID showed:
• Reduced time to recovery in certain hospitalized patients
• No clear mortality benefit once patients required mechanical ventilation
• WHO Solidarity trial: no statistically significant overall mortality reduction
In short: remdesivir was not a miracle drug. It was a modest antiviral deployed at extraordinary scale.
The Other Side: Ivermectin Advocates
Simultaneously, some frontline physicians and organizations in particular Dr. Cory of the Front Line Doctors of America FLCCC — advocated ivermectin as an off-label treatment based on observational data and early small studies and testified under oath at Congress hearings expounding the successes of Ivermectin as a protocol, safe and truly effective.
Regulatory bodies and major health authorities maintained that available evidence was insufficient to recommend it for COVID treatment.
This became one of the most polarizing disputes of the pandemic.
And it is within that dispute that Dr Wheeler practiced.
The New Zealand Case
Dr Caroline Wheeler prescribed ivermectin for a patient in late 2021, to be used if he contracted COVID.
The Tribunal found:
• The prescription was not clinically appropriate
• There was insufficient acknowledgement of prevailing medical knowledge
• Consent documentation was inadequate
• There was no clear management plan
The patient later experienced seizures after contracting COVID and taking ivermectin. But the question is would the patient have died taking Remdezivir? Statitistics are very hard to find but there are many whistleblower testimonies and affidavits showing the ineffectiveness of the approved Covid treatment protocol.
The Tribunal ruled her conduct amounted to professional misconduct.
Supporters argue she was exercising clinical discretion and the hypocratic oath 'do no harm'.
The Tribunal concluded she deviated from accepted standards.
That is the legal reality.
The Moral Hazard Question
Here is where the broader issue emerges.
When:
• Patent-protected therapeutics generate billions
• Emergency liability shields reduce manufacturer risk
• Governments embed specific drugs into official protocol
• And doctors prescribing outside that protocol face discipline
The public inevitably asks whether the system allows genuine clinical independence.
This is not about proving corruption.
It is about recognizing incentive gravity.
Publicly traded pharmaceutical firms exist to generate profit.
That is structural reality.
When emergency powers amplify profit opportunity and compress debate, institutional alignment becomes safer than dissent.
And doctors who deviate — even in good faith — may find themselves professionally exposed.
The Hippocratic Oath
The Hippocratic oath binds physicians to act in the patient’s best interest.
But modern medicine also binds them to regulatory compliance.
During COVID, those two obligations collided.
Dr Wheeler’s case is not simply about ivermectin.
It is about the narrowing of acceptable clinical latitude during crisis governance.
Whether one agrees with her clinical judgment or not, the deeper issue remains:
Can doctors question dominant protocol without fear?
If the answer is no, then medicine risks becoming administrative rather than independent.
Doctors in Chains
The chains are not prison bars.
They are regulatory structures, professional codes, and crisis-era enforcement standards.
When billions flow upward and individual physicians face disciplinary hearings, the optics matter.
Trust in medicine depends not only on outcomes — but on visible independence.
The public must believe that doctors are free to act for patients, not constrained by economic gravity or institutional conformity.
That trust is fragile.
And once fractured, it is hard to restore.